The share price of "Pharma first brother" of "Pharma fast reading society" has reached a new record with a market value of more than 400 billion yuan

On the evening of October 26, the State Council issued the opinions of the CPC Central Committee and the State Council on promoting the inheritance, innovation and development of traditional Chinese medicine According to the opinion of the State Council, we will study and cancel the work related to the addition of Chinese herbal pieces (cypress blue) On October 25, the State Administration of marketing issued the announcement on the third public consultation on the administrative measures for the examination of advertisements of drugs, medical devices, health food and formula food for special medical purposes (Draft for comments) The measures has made basic requirements for advertisements of drugs, medical devices, health food and formula food for special medical purposes (pharmacy manager) Today, the stock price of Hengrui Pharmaceutical Co., Ltd reached a new record of 91.08 yuan / share, with a market value of 402.83 billion yuan as of the latest publication Previously, the third quarter report of Hengrui pharmaceutical showed that in the first three quarters of this year, the revenue was 16.945 billion yuan, up 36.01% year-on-year; the net profit was 3.735 billion yuan, up 28.26% year-on-year (Sina Medical News) On October 28, AXA pharmaceutical officially went public on the Hong Kong stock exchange The IPO price is HK $34.20/share, with a total of 1218000 shares issued and the opening price of HK $48 / share It is reported that prior to the global offering and placement period, AXA pharmaceutical set the IPO record with the highest oversubscription multiple in this year with an oversubscription of 751 times, topping the "2019 Hong Kong stock oversubscription king" (shell Society) On October 28, Beijing xunyin Biotechnology Co., Ltd announced the completion of tens of millions of pre-A rounds of financing invested by German Union capital This round of financing will be mainly used for the commercial promotion of the company's single cell sequencing kit and the research and development of multiple single cell detection technologies It is reported that in October 2018, seeker received Angel round investment from Zhenge fund (Sina Medical News) On October 27th, meinian Health announced that the company's controlling shareholder Shanghai Tianyi Asset Management Co., Ltd., the person acting in concert and other shareholders signed the share transfer agreement with Alibaba network, Hangzhou xintou and Shanghai Qijun respectively Alibaba network and Hangzhou xintou, acting in concert, jointly acquired 10.82% of meinian health's shares, becoming the second largest shareholder, while Shanghai Qijun's acquisition of 5.34% of meinian health's shares is closely related to Alibaba (Sina Medical News) On October 27, Jiangsu Wuzhong Industrial Co., Ltd issued a notice, and the board of directors recently received a written resignation report submitted by Mr Wang Xiaogang, President (General Manager) of the company Mr Wang Xiaogang applied for resigning as president (General Manager) of the company due to personal reasons After resigning, he still served as a director of the company and a member of the enterprise development and Strategic Investment Committee under the board of directors (cypress blue) Recently, Zealand Pharma, a Danish biomedical company focused on peptide drug research and development, announced that it would buy cycle therapeutics, a Toronto based biotechnology company, for us $80 million Cycle has an advanced biotechnology platform that can rapidly synthesize new macrocyclic peptides The acquisition aims to strengthen the peptide drug development of zelaland and its leading position in the field of gastrointestinal disease treatment (yaomingkant) On October 28, Xin Lijun, CEO of JD health, announced at the 2019 JD health partner conference that JD health will launch a new strategy around the pharmaceutical supply chain, medical services and chronic disease management, launch a new drug poverty alleviation plan, a new barefoot doctor plan and a new chronic disease prevention plan, and in the future, it will establish a full chain and full cycle health management service around users (arterial network) In 2017, Gilead launched two studies (nct03134222 and nct03100942) targeting women with moderate to severe lupus erythematosus and Sjogren's syndrome, with results planned for the second half of 2019 Recently, John sundy, senior vice president of Geely's third quarter performance conference call, revealed that despite the "positive evidence" seen in previous studies, the final two trials did not reach the main end point (Sina Medical News) A year ago, Amgen announced that it would sharply reduce the price of repatha, PCSK9 cholesterol drug, from $14520 to $5850 by the end of 2020, causing a stir in the industry Recently, Amgen said that repatha will be sold exclusively for $5850 starting from January 2020, which shows that Amgen's commitment has been fulfilled in advance (Sina Medical News) Recently, y-mabs therapeutics announced at the annual meeting of the international children's cancer association that its humanized monoclonal antibody, naxitamab, targeting gD2 antigen, combined with GM-CSF, has obtained positive efficacy and safety data in clinical trials for children with neuroblastoma and osteosarcoma (yaomingkant) Recently, Baiyunshan announced that the clinical phase I trial of ceftriadimeform sodium for injection, a new class 1 Chemical drug developed by Baiyunshan Pharmaceutical General Factory of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., was officially launched in the near future (meter net)